| Literature DB >> 25892995 |
Alireza Esteghamati1, Tina Mazaheri1, Mona Vahidi Rad1, Sina Noshad1.
Abstract
CONTEXT: Obesity and its associated morbidities pose a major health hazard to the public. Despite a multiplex of available diet and exercise programs for losing and maintaining weight, over the past years, interest in the use of complementary and alternative medicine (CAM) for obesity treatment has greatly increased. EVIDENCE ACQUISITION: We searched PubMed, Google scholar and the Cochrane databases for systemic reviews, review articles, meta-analysis and randomized clinical trials up to December 2013.Entities:
Keywords: Acupuncture Therapy; Biliopancreatic Diversion; Complementary Therapies; Dietary Supplements; Laser Therapy; Obesity; Treatment Outcome; Weight Loss
Year: 2015 PMID: 25892995 PMCID: PMC4386228 DOI: 10.5812/ijem.19678
Source DB: PubMed Journal: Int J Endocrinol Metab ISSN: 1726-913X
Summary of the Available Evidence on Complementary and Alternative Medicine Methods Used for the Treatment of Overweight/Obesity
| Methods Name | Main Mechanism of Action | Strength of Publication | Effect Size | Possible Side Effects | |||
|---|---|---|---|---|---|---|---|
| Observational Studies/ Non-Randomized Trials | Randomized Clinical Trials | Systematic Review | Meta-Analysis | ||||
|
| |||||||
|
| Inhibition of citrate lyase enzyme, inducing satiety |
[ |
[ |
[ | 95% CI: 0.00 -1.75 kg | _ | |
|
| 1. Stimulation of sympathetic nervous system, leading to increase in energy consumption2. Fat oxidation |
[ |
[ |
[ | Minor (e.g. rhinitis, joint pain) | ||
|
| Stimulation of neurotransmitters responsible for eating behaviors |
[ | Non-specific and well tolerated (e.g: nausea, watery stools, weakness, dizziness) | ||||
|
| Not fully understood |
[ | 95% CI: 0.86 -1.79 kg | Mild gastrointestinal complaints | |||
|
| Inhibiting appetite by altering the neuropeptide pathways of the central nervous system |
[ |
[ | n/a [ | |||
|
| Appetite inhibiting effects, similar to |
[ | n/a [ | ||||
|
| Reducing nutritional fat absorption |
[ |
[ |
[ | 95% CI: 2.10 -1.30 kg | Mild gastrointestinal complaints (e.g. nausea, bloating, indigestion, abdominal pain), comparable to placebo | |
|
| Inhibiting adipogenesis? (not yet confirmed) |
[ | n/a [ | ||||
|
| |||||||
|
| 1. Regulating obesity-related neuropeptides, 2. Regulating Hypothalamus-pituitary-adrenal cortex and sympathetic-adrenal cortex, 3. Lipid lowering effects |
[ |
[ |
[ | 95% CI: 0.74 -2.38 kg (compared with sham); 0.50 - 2.93 (compared with lifestyle control) | Mild local reactions at the site of needle insertion | |
|
| |||||||
|
| 1. Hyperthermia, 2. Cavitation formation |
[ | Mild localized adverse events, e.g: erythema. | ||||
|
| Forming temporary pores in adipocytes’ membrane |
[ | No adverse events reported | ||||
|
|
[ | Localized edema and erythema, decreased cutaneous sensation | |||||
|
| Increasing tissue temperature |
[ | Mild and localized side-effects | ||||
aDenotes the type of evidence available for each method.
b n/a, no data available or no side effects have been reported.